A carregar...

Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility

Baloxavir marboxil (BXM) was approved in 2018 for treating influenza A and B virus infections. It is a first-in-class inhibitor targeting the endonuclease activity of the virus polymerase acidic (PA) protein. Clinical trial data revealed that PA amino acid substitutions at residue 38 (I38T/F/M) redu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Proc Natl Acad Sci U S A
Main Authors: Jones, Jeremy C., Pascua, Philippe Noriel Q., Fabrizio, Thomas P., Marathe, Bindumadhav M., Seiler, Patrick, Barman, Subrata, Webby, Richard J., Webster, Robert G., Govorkova, Elena A.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7165484/
https://ncbi.nlm.nih.gov/pubmed/32217734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1916825117
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!